Posted by AGORACOM-JC
at 9:11 AM on Thursday, February 11th, 2021
Announced that it has expanded its global reseller network with a partnership with Sport-Orthèse ( www.sport-orthese.com ), activating its country-specific scalable business model.
Toronto, New York – February 11, 2020 – Binovi Technologies Corp., (Binovi) (TSXV:VISN ) | ( OTC:BNVIF ) | ( GR:2EYA) today announces that it has expanded its global reseller network with a partnership with Sport-Orthèse ( www.sport-orthese.com ), activating its country-specific scalable business model. This move demonstrates Binovi’s ongoing efforts to optimize its revenue opportunities within its global strategy.
“As Binovi continues to successfully implement its global reseller partnerships, we remain dedicated to serving our consumers more personally and investing in the company’s long-term growth opportunities. In working with Sport-Orthèse, we’re signalling our dedication to our European clientele and furthering our goal for continued success on the continent” said Adam Cegielski, Binovi Founder + CEO.
Binovi remains firmly committed to serving users through its global partners with best-in-class product innovations and customer service while leveraging partnerships to support sustainable, profitable growth world-wide. In addition to this new connection to the EU, the Company will continue to work with existing distribution partner Bernell Corporation in the United States.
“We continue to broaden our customer base and aim to provide the best possible experience, especially with respect to working with customers in their native language whenever possible. Sport-Orthèse has the reach and capabilities to ensure Binovi is well represented in the European market,” commented Binovi Executive Chairman Terry Booth.
Posted by AGORACOM
at 8:54 AM on Thursday, February 11th, 2021
John Newell is a portfolio manager at Fieldhouse Capital Management and president and CEO of Golden Sky Minerals Corp.
He has 38 years of experience in the investment industry acting as an officer, director, portfolio manager and investment advisor with some of the largest investment firms in Canada including Scotia McLeod, CIBC Wood Gundy and Richardson Greenshields (RBC Capital Markets).
Newell is a specialist in precious metal equities and related commodities, and follows a disciplined proprietary approach incorporating equity research, analytical frameworks and risk controls to evaluate and select long and short stocks primarily from the Canadian small and mid-cap coverage.
Many large, midcap and junior precious metal companies use his technical charts. Newell is a registered portfolio manager in Canada (advising representative).
Two days ago industry specialist John Newell put out charts showing AMK was undervalued by 74% You can view that email here.
Posted by AGORACOM-JC
at 8:47 AM on Thursday, February 11th, 2021
Announced that it has advanced field testing of the EagleEye™ land mine detection solution with Windfall Geotek (TSX-V: WIN) (OTCQB: WINKF).
Windfall Geotek is a mining services company and a leader in the use of Artificial Intelligence (AI) and advanced knowledge-extraction techniques since 2005 in the mining sector.
This test included joint research, AI development, and engineering support for the development of drones and sensor equipment.
Los Angeles, CA., Feb. 11, 2021 — Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer, today announced that it has advanced field testing of the EagleEye™ land mine detection solution with Windfall Geotek (TSX-V: WIN) (OTCQB: WINKF).
Windfall Geotek is a mining services company and a leader in the use of Artificial Intelligence (AI) and advanced knowledge-extraction techniques since 2005 in the mining sector. This test included joint research, AI development, and engineering support for the development of drones and sensor equipment.
Every day approximately 10 people around the world lose their lives or are maimed due to an anti-personnel mine (” APM “). This means that about 4,200 people are hurt or killed worldwide every year of which 35-42% are estimated to be children. It is estimated that there are between 60-110 million landmines in the ground right now and an equal amount is in stockpiles waiting to be planted or destroyed. Approximately 82 countries around the world are contaminated by APMs. Source: United Nations, Office for Disarmament Affairs .
An estimated US$540,000,000 was spent by industry and government in 2018 to deal with this problem of Landmines and Explosive Remnants of war (identify multiple APM and improvised explosive devices (IEDs) in a variety of terrain and contexts). Source: Landmine Monitor Report 2019 .
“Since 2020, Draganfly has invested in new capabilities in drone-based magnetometer technology and other remote sensing equipment,” commented Dinesh Kandanchatha, Chairman of Windfall Geotek. “The depth of the Draganfly engineering team, drone services group, and expert advisory in public safety was instrumental to get us to these first tests.”
“Windfall Geotek is the industry leader in AI-based digital exploration for mining. We now have the right mixture of equipment and data to move to the commercialization of an advanced AI-based platform to help solve the global problem of landmines,” said Cameron Chell, CEO of Draganfly. “The two companies share a mission of saving lives through technology. These tests are critical to helping create a new solution to this age-old problem. The new and expanded revenue streams for both companies in the Defense sector, Public Safety, and other markets are significant and represent an area where combined offering can excel.”
“For years our foundation has support organizations removing land mines, this type of technology and innovation by Draganfly and Windfall is exactly what is needed to solve this global challenge on a massive scale,” said Admiral Hayward, former head of the US Navy and member of the Joint Chiefs of Staff.
Posted by AGORACOM-JC
at 8:43 AM on Thursday, February 11th, 2021
Agreement will help fuel Liquid Avatar’s expansion to the UK and Caribbean.
Entered into an initial agreement with the Gibraltar holding company of London, UK and St. Michael’s, Barbados based Tokenise International Limited (“Tokenise”) (www.tokenise.io), a multi-jurisdictional regulated financial services organization.
Together, the Companies are working on initiatives to integrate Liquid Avatar with Tokenise and issue verifiable identity credentials to account holders and to use these credentials to gain access to Tokenise financial and brokerage services and other related platforms, starting in the UK and Barbados.
TORONTO, CA and LONDON, UK and ST. MICHAELS, BARBADOS / February 11, 2021 / KABN Systems NA Holdings Corp. (CSE:KABN)(OTC PINK:TRWRF)(FRA:4T51) (the “Company“, “KABN North America” or “KABN NA“) (www.kabnsystemsna.com), a North American Fintech solutions company specializing in empowering individuals to manage, control and generate value from their biometrically verified Self Sovereign Identity (“SSI”) through its Liquid Avatar (www.liquidavatar.com) platform, is pleased to announce that it has entered into an initial agreement with the Gibraltar holding company of London, UK and St. Michael’s, Barbados based Tokenise International Limited (“Tokenise”) (www.tokenise.io), a multi-jurisdictional regulated financial services organization.
Together, the Companies are working on initiatives to integrate Liquid Avatar with Tokenise and issue verifiable identity credentials to account holders and to use these credentials to gain access to Tokenise financial and brokerage services and other related platforms, starting in the UK and Barbados.
Tokenise operates Kession Capital Limited, a London-based broker dealer that is authorized and regulated by the Financial Conduct Authority in the United Kingdom. Tokenise offers issuers and investors the ability to tokenize crowdfunding programs through the purchase, sale, and exchange of blockchain based securities. Kession also acts as a UK conduit to the Tokenise Stock Exchange, a fully regulated stock exchange in Barbados providing global primary issuance and secondary market trading, promoting financial inclusion and asset diversification, and focusing exclusively on tokenized securities and Tokenise Brokerage to support the onboarding efforts of global investors. Tokenise is also exploring expansion opportunities into Canada.
With Digital Identity applications addressable to up to 100% of the online market, the financial services market is a primary opportunity for Liquid Avatar’s Verifiable Credentials Ecosystem announced earlier this month. By accessing a biometrically enabled verifiable identity credential that a user can store in their Liquid Avatar wallet, Tokenise will be able to verify and validate customers allowing them to securely and safely access their accounts based on their known and verified digital identity. The program is expected to commence by early Q3 2021.
Posted by AGORACOM-JC
at 8:38 AM on Thursday, February 11th, 2021
Closed its acquisition of 100% of Concierge Medical Consultants Inc.’s (“Concierge“) issued and outstanding securities (the “Transaction“), pursuant to terms of the share exchange agreement entered into between the Company, Concierge, and the shareholders of Concierge (the “Concierge Shareholders“) effective January 19, 2021 (the “Definitive Agreement“).
Concierge is an arm’s length private telehealth and medical concierge services
Toronto, Ontario–(February 11, 2021) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex“) is pleased to announce that further to its press releases dated January 7, 2021 and January 22, 2021, it has closed its acquisition of 100% of Concierge Medical Consultants Inc.’s (“Concierge“) issued and outstanding securities (the “Transaction“), pursuant to terms of the share exchange agreement entered into between the Company, Concierge, and the shareholders of Concierge (the “Concierge Shareholders“) effective January 19, 2021 (the “Definitive Agreement“).
Concierge is an arm’s length private telehealth and medical concierge services company incorporated under the laws of British Columbia.
Terms of the Transaction
Pursuant to the Definitive Agreement, the Company issued 4,411,764 common shares in the capital of the Company (the “Common Shares“) to the Concierge Shareholders at a price of $0.17 per Common Share for an aggregate purchase price of $750,000.
No finder’s fee was payable in connection with the Transaction.
“Hospital ER’s and health practitioners’ clinics are making a strong push for patients who have mild symptoms to use telehealth platforms during the pandemic crisis to help alleviate the strain on emergency rooms and doctors’ offices and I believe this will continue after the pandemic crisis is over,” commented Dr. Jibran Sharif, MD, founder, and CEO of Concierge.
“Telemedicine visits are booming as doctors and patients have adopted social distancing amid the coronavirus crisis, and with the concierge services Dr. Sharif provide, we envision an end to end turnkey solution for patient healthcare,” said Marshall Gunter, CEO of Datametrex, with respect to the closing of the Transaction.
Operations of Concierge Upon Completion of the Transaction
Concierge has become a wholly-owned operating subsidiary of the Company. The Company has appointed Andrew Ryu, Marshall Gunter, and Dr. Jibran Sharif as the new board of the directors of Concierge, and Dr. Sharif is appointed as the President of Concierge following the closing of the Transaction (the “Closing“). In addition, concurrent with the Closing, the Company has entered into a employment agreement with the founder and President of Concierge, Dr. Jibran Sharif. In addition to his role as President of Concierge, Dr. Jibran Sharif will become the Chief Medical Officer of Datametrex.
Posted by AGORACOM-JC
at 8:20 AM on Thursday, February 11th, 2021
Cedar Clinical Research to be Evaluated to Support Phase IIb Trial of Novel PTSD Treatment
Announced that it has made a strategic investment of AU$827,486 (approximately CAN$810,000, the “Strategic Investment”), in Bionomics Limited (“Bionomics”) (ASX:BNO)(OTCQB:BNOEF) (Germany:AU000000BNO5), a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders.
In addition, Cedar Clinical Research (“CCR”), a wholly owned subsidiary of Novamind based in Springville, Utah, will be evaluated by Bionomics as a clinical research site to conduct Bionomics’ Phase IIb trial examining BNC210.
BNC210 has received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of post-traumatic stress disorder (PTSD).
TORONTO, ON / February 11, 2021 / Novamind Inc. (CSE:NM) (“Novamind”), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has made a strategic investment of AU$827,486 (approximately CAN$810,000, the “Strategic Investment”), in Bionomics Limited (“Bionomics”) (ASX:BNO)(OTCQB:BNOEF) (Germany:AU000000BNO5), a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders.
In addition, Cedar Clinical Research (“CCR”), a wholly owned subsidiary of Novamind based in Springville, Utah, will be evaluated by Bionomics as a clinical research site to conduct Bionomics’ Phase IIb trial examining BNC210. BNC210 has received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of post-traumatic stress disorder (PTSD).
With its investment in Bionomics, Novamind joins a group of well-known investors that specialize in psychedelics and biotech: Apeiron Investments, Biotech Value Fund, Merck & Co., Mike Novogratz, and Peter Thiel, an early investor in ATAI Life Sciences.
Novamind’s Strategic Investment is included in Bionomics’ latest round of financing, which was underwritten by Apeiron Investments and received commitments for AU$16,000,000 (approximately CAN$15,680,000, the “Bionomics Financing”). Novamind will purchase a total of 5,706,800 common shares in the Bionomics Financing, at AU$0.145 per share, a 20% discount to the 30-day volume weighted average price as of February 5th, 2021. Proceeds from the Bionomics Financing will support the initiation of a Phase IIb trial for BNC210, planned for mid-2021.
Bionomics intends to evaluate Cedar Clinical Research’s deep expertise in facilitating Phase I to Phase IV clinical trials for leading pharmaceutical companies, and how it may potentially serve as a research site for Bionomics’ Phase IIb clinical trial examining BNC210 in PTSD patients.
Cedar Clinical Research, led by Novamind’s Chief Medical Officer, Dr. Reid Robison, is currently contracted for seven clinical trials with various sponsors, including leading pharmaceutical companies. Dr. Robison has led over 100 clinical trials in neuropsychiatry, researching a spectrum of psychiatric conditions, including PTSD.
“I’m happy to welcome Novamind as a strategic investor in Bionomics,” said Dr. Errol De Souza, Executive Chairman of Bionomics. “Dr. Robison and the team at Cedar Clinical Research have unique experience related to clinical trials for mental health therapeutics.”
Yaron Conforti, CEO and Director of Novamind, added, “We are pleased to participate in Bionomics’ financing to support the development of its novel drug candidate for the treatment of PTSD. Cedar Clinical Research has unique expertise in PTSD research, and we look forward to the opportunity to contribute to the development of BNC210.”
Bionomics is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics’ lead drug candidate BNC210, currently in development for initiation of a second Phase II trial for the treatment of PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada). To learn more, please visit bionomics.com.au.
About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.
Contact Information
Novamind Yaron Conforti, CEO and Director Telephone: +1 (647) 953 9512 Bill Mitoulas, Investor Relations Email: [email protected]
Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.
Posted by AGORACOM-JC
at 6:33 PM on Wednesday, February 10th, 2021
The paradigm shifting, parabolic growth of plant based foods and a plant based life is unstoppable, with the plant-based food market alone expected to reach $74.2 billion by 2027.
If you believe in the massive paradigm shift towards plant based foods and more, be sure to watch and share this great interview with PlantX Founder Sean Dollinger.
Posted by AGORACOM
at 4:18 PM on Wednesday, February 10th, 2021
St-Georges Eco-Mining Corp. (CSE:SX)(OTC:SXOOF) (FSE:85G1) (CNSX:SX.CN)is pleased to announce a non-brokered private placement offering of units at a price of $0.50 and “flow-through” units at a price of $0.60 as well for total gross proceeds of up to $10,000,000.
Each Unit is comprised of one (1) common share (each, a “Share”) in the capital of the Corporation and one (1) Share purchase warrant (each, a “Unit Warrant”), entitling the holder to purchase one (1) Share at an exercise price of $0.65 until first 18 months from the issuance and $1.05 for the 18 months thereafter, together 36 months expiry period (the “Unit Warrant Expiry Date”).
Each FT Unit is comprised of one (1) common share in the capital of the Company on a “flow-through” basis (each, a “FTShare”) and one (1) FT Share purchase warrant (each, a “FT Warrant”). Each FT Warrant entitles the holder thereof to purchase one (1) Share at an exercise price of $0.75 until first 18 months from the issue and $1.25 for the 18 months thereafter, together 36 months expiry period (the “FT Warrant Expiry Date”, together with the Unite Warrant Expiry Date, the “Warrant Expiry Date”).
Posted by AGORACOM
at 12:37 PM on Wednesday, February 10th, 2021
School BUSRide spoke with Kevin Moore, CEO of SOBRsafe™, about touch-based alcohol detection and the difference it can make for school transportation
Kevin Moore, Chief Executive Officer, said that for he and SOBRsafe™, child safety represents a chance to make a societal difference with breakthrough technology.
Originally formed by venture capital firm First Capital Ventures, and merged with a detection technology development company, SOBRsafe is at its core a technology and data platform for touch-based alcohol detection – and it is coming to school buses.
“We brought a lot of previously successful people together as the leadership at SOBRsafe,” Moore said. “And one of the key elements for that leadership is to make a difference with this company. We are all at the point in our lives where we want to leave a generational legacy – and child safety is an area where we can make a significant social impact.”
Moore said that American school transportation lacks tools to fully prevent impaired driving, through no fault of the districts and schools themselves. With current capabilities and requirements, alcohol impairment can often go untracked at school bus operations – or tracked with very limited or random screening techniques.
“Every parent treasures their child’s safety,” Moore said, “so we asked ourselves, ‘What if we had a solution that screens 100 percent of bus drivers before they can receive keys and operate a bus?’”
SOBRcheck™
After a lengthy research and development period, SOBRsafe is launching SOBRcheck™ for access control, a patent-pending, proprietary device that provides touch-based identity verification and alcohol detection via a “go/no go” methodology.
When a human ingests alcohol, one of the ways it leaves the body is via transdermal expiration – through the skin. The SOBRcheck™ device does not provide a Blood Alcohol Content (BAC) reading, instead detecting the presence of alcohol in Zero Tolerance situations – like a school bus operation.
The system further functions as a driver/vehicle authenticator by beaming light onto a driver’s skin and creating a set of data points. Those data points then act as that driver’s unique identification. Moore said that this helps alleviate privacy concerns, as the device is not recording fingerprints.
Furthermore, the information that the device collects is immediately transmitted to supervisors via a user-friendly app. This process, Moore said, allows transportation managers, operation managers, and other supervisors to make proactive decisions as opposed to reactive corrections.
“This is the sort of tool which will not only allow school transportation departments to keep children safe, but also provide parents with peace of mind about their child on the bus,” Moore said. “We see preemptive alcohol detection as a critical need for school buses, and feel this device is a phenomenal way to fulfill that need. Systems like this can be essential to ensure that school buses are substance-free environments.”
Kevin Moore, Chief Executive Officer, said that for he and SOBRsafe™, child safety represents a chance to make a societal difference with breakthrough technology.
A unique model
Moore said that SOBRsafe’s intellectual property is currently focused on alcohol detection, but the company is exploring technology centered around detection of cannabis, opioids, and other illicit drugs – as driven by employer need and market demand.
“The key to SOBRsafe is that we are not out developing technologies that require years of testing before commercialization,” Moore said. “We are an integrator of technologies. So, in addition to our internal alcohol detection development, we are looking for other commercially-ready technologies that might work within our system architecture.”
In addition to pursuing other substance detection solutions, Moore said that SOBRsafe is continuing to develop additional value-added features for its devices. The company is launching a new employee health and wellness platform soon, and is implementing GPS location, temperature checks, and more physiology-based technology into its devices for future deployments.
“There is a tremendous amount of emerging technology that can provide a huge benefit for schools and transportation operations,” he said. “We just have to find it, prove its effectiveness, and integrate it into our solutions.”
Deploying to school buses
Moore said that SOBRsafe moved through several prototypes and multiple human trials of the SOBRcheck device, as refining the technology’s various algorithms and detection processes is an exacting, time-consuming task. This was especially so in the wake of the nation’s COVID-19 shutdowns, extending the time required for effective pilot programs.
Once the current round of “production tooling” is complete, the company will launch another pilot program – and then go to market for school districts in the second quarter of 2021.
“We are accelerating the intervention process for school districts,” he said. “Driving under the influence is a serious matter, and intervention can reduce accidents, litigation, deaths, and operating costs.”
More than anything, Moore said, the company’s core objective is safety and saving lives, with child safety at the forefront.
“The feedback we are getting is extremely positive because there is a need in pupil transportation that has not been properly addressed with legacy technology,” Moore said. “When supervisors can proactively make critical decisions by using this data, it is going to improve productivity and save lives.”
